依达拉奉联合奥扎格雷钠治疗急性脑梗死疗效对比分析

目的：进一步研究和比较临床治疗急性脑梗死实践过程中采用依达拉奉联合奥扎格雷钠治疗方法的实际治疗效果,从而为临床实践提供指导和依据。方法：以本院2010年12月-2012年12月收治的急性脑梗死患者92例为研究对象进行了回顾性分析。结果：实施治疗前,两组患者的NIHSS评分和ADL指数评分结果比较差异无统计学意义;实施治疗后14 d和30 d,联合用药组患者的NIHSS评分和ADL指数评分结果显著地低于单纯用药组患者水平,比较差异具有统计学意义（P〈0.05）。结论：在临床针对急性脑梗死患者实施治疗的过程中采用依达拉奉联合奥扎格雷钠治疗方法的临床治疗效果显著,是临床治疗急性脑梗死患者的安全可靠选择。

The Comparative Analysis of Edaravone Combined with Ozagrel in the Treatment of Acute Cerebral Infarction

Objective： To further study and compare the clinical treatment of edaravone combined with ozagrel in the treatment of acute cerebral infarction, so as to provide guidance and basis for clinical practice. Method： 92 patients with acute cerebral infarction in our hospital from December 2010 to December 2012 were chosen as the research object. And they were taken for retrospectively analysis. Result： In the comparison of NIHSS score and ADL index score, implementation before treatment, compared between groups, the score of NIHSS scale and ADL index in the patients of the two groups had no difference, there was no significant difference. 14 days and 30 days after the implementation, compared between groups, the scores of NIHSS scale and ADL index in the combination group were significantly lower than the that in patients with simple drug group, the difference was statistically significant （ P〈0.05 ） . Conclusion： The clinical treatment effect of edaravone combined with sodium ozagrel in the treatment of patients with acute cerebral infarction is remarkable, and it is a safe and reliable choice for the clinical treatment of patients with acute cerebral infarction.